MedCity News October 2, 2022
Sudo Bioscience emerged with $37 million in funding and four programs that address TYK2, a promising target for autoimmune diseases. Bristol Myers Squibb drug Sotyktu recently won the first FDA approval for a TYK2 inhibitor but Sudo claims its molecules have the potential to be best in this new drug class.
Immunology drug research has been casting about for better and safer ways to intervene in the inflammation driving autoimmune disorders. The recent FDA approval of a Bristol Myers Squibb plaque psoriasis drug made it the first approved product in a new class of medicines that address a particularly attractive enzyme target. Startup Sudo Biosciences aims to show that its drugs can be best in this emerging class, and it...
Today's Sponsors
Today's Sponsor